Novo Nordisk A/S

Unternehmens-Profil

Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial insulin production began in Denmark following its discovery. Headquartered in Bagsværd, Denmark, the company employs over 77,000 people worldwide and markets products in more than 168 countries. It holds a leading position in diabetes care, commanding roughly one-third of the global branded market with insulins like Tresiba and Levemir, and GLP-1 therapies such as Ozempic and Rybelsus. Novo Nordisk A/S also excels in obesity treatments with Wegovy and Saxenda, alongside therapies for rare diseases including hemophilia (NovoSeven, Esperoct), growth disorders (Norditropin), and hormone replacement. Its biopharmaceutical innovations, including smart insulin pens and delivery systems, underscore its commitment to accessibility and patient-centered solutions, significantly influencing healthcare sectors focused on metabolic, cardiovascular, and endocrine conditions.

Bewertungs-Kennzahlen

Allgemeine Finanzkennzahlen

Chart · 90 Tage

Letzter Kurs: 39,46 EUR· Stand 07.05.2026

News · Novo Nordisk A/S

• Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 marketProactive Investors · 08.05.2026
• Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptakeReuters · 08.05.2026
• Healthy Returns: First Ozempic generics in Canada will be a test case for Novo NordiskCNBC · 07.05.2026
• What the FDA's Latest Proposal Means for Lilly, Novo, and HimsMarketBeat · 07.05.2026
• Novo and Lilly gain on signs weight-loss pills could expand the marketReuters · 07.05.2026